Luxna Entered into a Collaboration Agreement with Servier for Drug Discovery Research to Treat Neurological Diseases
Shots:
-
The collaboration focuses to advance the development and practical application of oligonucleotide therapies by using Luxna XNAs Technology
-
In a short amount of time, Servier's lead antisense oligonucleotide compounds targeted against a potentially transformative therapeutic target in neurological diseases are optimized using Luxna's revolutionary xeno nucleic acid technology
-
By utilizing strengths of strong binding to mRNA and/or reduced toxicity, Luxna XNAs Technology may be able to produce ASOs with high activity and low toxicity
Ref: Luxna | Image: Luxna
Related News:- Servier Reports P-III Trial (INDIGO) Results of Vorasidenib for IDH-Mutant Low-Grade Glioma
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
